Camurus Investor Relations Material
Latest events
Q2 2024
Camurus
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from Camurus
Access all reports
Segment Data
Access more data
Revenue by
Products and services
Product sale
Sales of development-related goods and services
Licensing revenues and milestone payment
Expenses by
Financials
Camurus AB is a pharmaceutical company developing and commercializing medicines for severe and chronic conditions. Camurus AB's product portfolio includes PRADAXA, which is indicated for the reduction of the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation; TYSABRI for multiple sclerosis (MS) and psoriatic arthritis; DIFICID for antibiotic-associated diarrhea (AAD); EURAX for ulcerative colitis; and ORAPAVAN for nephrotic syndrome. Camurus AB is based in Lund, Sweden.
Key slides for Camurus
Q2 2024
Camurus
Company Presentation
Camurus
Latest articles
The Birkin Bag: The Story Behind the World's Most Desired Handbag
How the Birkin bag became the world's most sought-after handbag where even the wealthy must earn the right to own one.
12 Jul 2024
The 10 Largest Semiconductor Companies in the World
Discover the top 10 semiconductor companies by market cap, exploring their innovations and business models shaping the tech landscape.
10 Jul 2024
The Rise of Nubank: Changing Latin American Finance
Discover how Nubank revolutionized Latin American banking with innovation, backed by top investors like Berkshire Hathaway.
9 Jul 2024
Ticker symbol
CAMX
Country
🇸🇪 Sweden